Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$39.5 - $57.22 $10.7 Million - $15.5 Million
-270,300 Reduced 40.45%
398,000 $17.6 Million
Q1 2024

May 15, 2024

SELL
$55.06 - $69.99 $919,502 - $1.17 Million
-16,700 Reduced 2.44%
668,300 $37.5 Million
Q4 2023

Feb 14, 2024

SELL
$57.25 - $69.74 $16.1 Million - $19.7 Million
-282,000 Reduced 29.16%
685,000 $41.2 Million
Q3 2023

Nov 14, 2023

BUY
$63.16 - $76.5 $10.6 Million - $12.9 Million
168,100 Added 21.04%
967,000 $65 Million
Q2 2023

Aug 14, 2023

SELL
$46.28 - $75.01 $14.9 Million - $24.1 Million
-321,600 Reduced 28.7%
798,900 $55.1 Million
Q1 2023

May 15, 2023

BUY
$43.42 - $57.37 $6.53 Million - $8.63 Million
150,500 Added 15.52%
1,120,500 $54 Million
Q4 2022

Feb 14, 2023

BUY
$38.8 - $55.46 $37.6 Million - $53.8 Million
970,000 New
970,000 $48.4 Million
Q2 2022

Aug 15, 2022

SELL
$33.54 - $55.0 $3.19 Million - $5.23 Million
-95,000 Reduced 8.68%
1,000,000 $55 Million
Q1 2022

May 16, 2022

BUY
$31.02 - $48.18 $11.9 Million - $18.5 Million
383,100 Added 53.81%
1,095,000 $39.8 Million
Q4 2021

Feb 14, 2022

SELL
$41.14 - $56.98 $7.49 Million - $10.4 Million
-182,100 Reduced 20.37%
711,900 $33.2 Million
Q3 2021

Nov 15, 2021

BUY
$35.31 - $50.56 $9.5 Million - $13.6 Million
269,000 Added 43.04%
894,000 $45.2 Million
Q2 2021

Aug 16, 2021

BUY
$25.8 - $41.09 $16.1 Million - $25.7 Million
625,000 New
625,000 $25.7 Million
Q3 2020

Nov 16, 2020

SELL
$27.5 - $39.61 $2.75 Million - $3.96 Million
-100,000 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$36.1 - $42.56 $3.61 Million - $4.26 Million
100,000 New
100,000 $4.26 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $5.49B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Avidity Partners Management LP Portfolio

Follow Avidity Partners Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.